Method of optimization of targeted therapy in patients with GIST generalized form
https://doi.org/10.25789/YMJ.2019.65.10
Abstract
In order to increase the effectiveness of treatment of patients with disseminated forms of gastrointestinal stromal tumors, work was done to optimize targeted therapy with imatinib based on monitoring its active metabolites in patients’ blood, and an algorithm for individualizing therapy was developed and applied in practice, depending on the obtained laboratory data and the results of physical examination.
About the Authors
C. T. Adleyba
Yaroslavl State Medical University
Russian Federation
Russian Federation
Adleyba Saria Temurovna, doctoral student from the Pharmacology Department
A. V. Sidorov
Yaroslavl State Medical University
Russian Federation
Russian Federation
Sidorov Alexander Vyacheslavovich, PhD in Medical Sciences. Assistant Professor of Pharmacology department, Head of Pharmacognosy and Pharmaceutical engineering department
L. M. Kogonia
MONIKI n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
Kogonia Lali Mikhailovna, PhD in Medical Sciences. professor of Oncology and Thoracic surgery Department
References
1. The value of molecular genetic markers for the prognosis and treatment of severe gastrointestinal tumors. Achievements and prospects of drug treatment of malignant tumors / N.N. Mazurenko, I.S. Belyakov, I.V. Tsyganova [et al.] // Etudes of chemotherapy III. Ed. V.A.Gorbunova. – М., 2011. – р. 111-126.
2. Kogonia L.M. Adjuvant therapy of patients with GIST / L.M. Kogonia, S.V. Mordanov, O.S. Oxenyuk // Malignant tumors. – 2014. – №1. – р.39-46.
3. Mutations of c-kit and PDGFRA genes and clinical and morphological features of stromal tumors of the gastrointestinal tract / I.S. Belyakov, O.A. Anurova, P.V. Snigur [et al.] // Oncology issues. – 2007. – V. 53. – №6. – р. 677-681.
4. Seryakov A.P. Gastrointestinal stromal tumors /A.P. Seryakov // Russian Journal of Gastroenterology, Hepatology, Coloproctology. – 2010. – V.20, №4. – р. 49-57.
5. Tsyganova I.V. Morphological features and criteria for the prediction of gastrointestinal stromal tumors I.V. Tsyganova, O.A. Anurova, N.N. Mazurenko // Pathology Archive. – 2011. – V. 73, №6. – р. 37-42.
6. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas / К. Antman, J. Crowley, S. Balcerzak [et al.] // J. Clin. Oncol. 1993;11(7): 1276-1285.
7. Antonescu C.R. Association of KIT exon 9 mutation with nongastric primary site and aggressive behavior: KIT emulation analysis and clinical correlates of 120 gastrointestinal stromal tumours / C.R. Antonescu, G. Sommer, L. Sarran // Clim.Cancer Res. – 2003. – N9. – P.3329-3337. http://dx.doi.org/10.4061/2011/708596
8. Corless C.L. Biology of gastrointestinal stromal tumors / C.L. Corless, J.A. Fletcher, M.C. Heinrich // J. Clin. Oncol. – 2004. – Vol. 9. – P.3329-3337. https://doi.org/10.1007/s00428-010-0891-y
9. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. C. Yoo, M.H. Ryu, B.W. Kang [et al.] // Clin. Oncol. 2010; 28: 1554-1559. http://dx.doi.org/10.1200/JCO.2009.26.5785
10. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor / C.H. Holdsworth, R.D. Badawi, J.B. Manola [et al.] // Am J Roentgenol. 2007; 189: 324-330. DOI:10.2214/AJR.07.2496
11. Effect of rifampicin on the pharmacokinetics of iraatinib mesylate (Gleevec, ST1571) in healthy subjects / A. Bolton, B. Peng, M. Hubert [et al.] – Cancer Chemother Pharmacol. – 2004 Feb;53(2): 102-106. DOI:10.1007/s00280-003-0722-9
12. Fletcher J.A. Proc. Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal stromal tumors / J.A. Fletcher, C.L. Corless, S. Dimitrijevic // Am. Soc. Clin. Oncol. – 2003; 22: 815 (A3275).
13. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable / metastatic gastrointestinal stromal tumors / G. Demetri, Y. Wang, E. Wehrle [et al.] // J Clin Oncol. – 2009; 27:3141-3147. DOI:10.1200/JCO.2008.20.4818
14. Kantarjian H.M. The MD Anderson Manual of Medical Oncology / H.M. Kantarjian. – 2nd. – McGraw-Hill, 2011. – ISBN 978-0-07-170106-8.
15. Miettinen M. Gastrointestinal Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival / M. Miettinen, J. Lasota // Pol. J. Pathol. – 2003. – №54. – р.3-24.
16. Mudan S.S., Woodruff J.M., Brenan M.F Ann. Surg. 2000. – V.231. – P.51-58. http://dx.doi.org/10.1097/00000658-200001000-00008
17. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors; the ADAGIO study / F. Mazzeo, L. Duck, E. Joosens [et al.] / Anticancer Res. 2011;31:1407-1409.
18. Patel S. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance / S. Patel // Cancer Treat Rev. 2012; 38(5): 467-72.http://dx.doi.org/10.1016/j.ctrv.2011.10.001
19. Rubin B.P. Gastrointastinal stromal tumours: an update / B.P. Rubin // Histopatology. – 2006. – Vol. 48. – P.83-96.DOI: 10.1111/j.1365-2559.2005.02291.x
20. Stromal tumours (GIST). Review on morphology, molecular pathology, prognosis and differential diagnosis // Arch. Pathol. Lab. Med. – 2006. – Vol. 130 – P.1466-1477. https://doi.org/10.1007/978-88-470-5310-6_8
21. Von Mehren М. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clnical response in advanced metastatic gastrointestinal stromal tumor: an emerging role for drug blood level testing? / М. Von Mehren, N. Widmer // Cancer Treat Rev 2011; 37: 291-299.Doi 10.1016/j.ctrv.2010.10.001
Review
For citations:
Adleyba C.T., Sidorov A.V., Kogonia L.M. Method of optimization of targeted therapy in patients with GIST generalized form. Yakut Medical Journal. 2019;(1):35-38. https://doi.org/10.25789/YMJ.2019.65.10
Views:
3
Email this article 